The advent of PSMA-targeted RLT signifies a substantial advancement in PCa management [30], built upon the “theranostic” principle of using a single molecular target for both diagnostic imaging and personalized therapy. This evidence concerns the gene FOLH1 and posterior cortical atrophy.